KPG-121, a novel cereblon modulator, in patients with metastatic castration resistant prostate cancer: Results of a phase I multiple ascending dose study. Baseline PSMA PET/CT as a predictive ...
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...
A research team at Osaka University will start an investigator-initiated clinical trial for refractory prostate cancer patients after successful development of a new alpha-ray therapeutic agent ...
Prostate cancer highlights from the American Urological Association 2025 meeting include quality-of-life results from the phase 3 PSMAfore study, findings on androgen deprivation therapy (ADT) with or ...
An exploration of how targeted nanoparticles and artificial intelligence algorithms combine to locate prostate cancer earlier ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results